Patients with advanced gastric cancer who were included in previous biomarker research in our hospital \((N=173)\)

\(\rightarrow\) Exclusion: tumor tissue samples were insufficient for direct-sequence method \((N=6)\)

Direct-sequence method of \textit{KRAS, NRAS, BRAF} and \textit{PIK3CA} mutations in AGC \((N=167)\)
(whole cohort)

Patients who underwent surgical resection without systemic chemotherapy (Group A)
Stage I to III patients who had no recurrence \((N=28)\)
Stage I to III patients who had recurrence \((N=5)\)
Stage IV patients who underwent only surgical resection \((N=6)\)
Transfer to another hospitals before systemic chemotherapy \((N=3)\)

Patients with metastatic/recurrent gastric cancer who received systemic chemotherapy \((N=125)\)
(Group B)

Figure 1. Diagram of this study